Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 33
-0.62%-1.87%+42.87%+64.15% 63.77B
+0.35%+3.20%+14.40%+81.76% 56.37B
+0.53%+1.96%+16.24%+103.35% 54.62B
-2.81%-4.31%+23.50%+47.83% 44.06B
-0.33%-1.93%+19.28%+98.80% 42.11B
+0.55%+2.31%+225.14%+866.21% 41B
+3.27%+47.96%+112.84%+96.58% 34.92B
+1.22%-1.44%+14.57%+46.95% 32.82B
+0.89%+20.55%-40.62%+349.24% 24.7B
Average +0.31%+7.54%+47.58%+194.99% 43.82B
Weighted average by Cap. +0.18%+5.44%+47.99%+176.67%
Logo ARYx Therapeutics, Inc.
ARYx Therapeutics, Inc. is a United States-based pharmaceutical Company. The Company is developing a proprietary portfolio of patient-targeted, first-in-class monoclonal antibodies designed to treat seriously ill patients with difficult-to-treat diseases. It is engaged in retrometabolic drug design that focuses on the safety of oral therapies for chronic disease. The Companys clinical compounds include naronapride (ATI-7505) for gastrointestinal disorders; budiodarone (ATI-2042, for the treatment of atrial fibrillation; tecarfarin (ATI-5923) for the treatment of anticoagulation; and ATI-9242, for psychiatric disorders.
Employees
56
  1. Stock Market
  2. Stocks
  3. ARYX Stock